These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 22542316)

  • 41. Cancer risk factors for selecting cohorts for large-scale chemoprevention trials.
    Greenwald P
    J Cell Biochem Suppl; 1996; 25():29-36. PubMed ID: 9027595
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Protein biomarker discovery and validation: the long and uncertain path to clinical utility.
    Rifai N; Gillette MA; Carr SA
    Nat Biotechnol; 2006 Aug; 24(8):971-83. PubMed ID: 16900146
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cancer biomarkers--an invitation to the table.
    Dalton WS; Friend SH
    Science; 2006 May; 312(5777):1165-8. PubMed ID: 16728629
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Proteomics: new technologies and clinical applications.
    Latterich M; Abramovitz M; Leyland-Jones B
    Eur J Cancer; 2008 Dec; 44(18):2737-41. PubMed ID: 18977654
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Multi-gene biomarker panel for reference free prostate cancer diagnosis: determination and independent validation.
    Cuperlovic-Culf M; Belacel N; Davey M; Ouellette RJ
    Biomarkers; 2010 Dec; 15(8):693-706. PubMed ID: 20883156
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Proteomic approaches in lung cancer biomarker development.
    Cho JY; Sung HJ
    Expert Rev Proteomics; 2009 Feb; 6(1):27-42. PubMed ID: 19210125
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Other biomarkers for detecting prostate cancer.
    Nogueira L; Corradi R; Eastham JA
    BJU Int; 2010 Jan; 105(2):166-9. PubMed ID: 19930175
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Biomarkers as molecular targets of drug interventions.
    Smith JJ; Dunn BK
    Semin Oncol Nurs; 2012 May; 28(2):109-15. PubMed ID: 22542318
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Considerations on development, validation, application, and quality control of immuno(metric) biomarker assays in clinical cancer research: an EORTC-NCI working group report.
    Sweep FC; Fritsche HA; Gion M; Klee GG; Schmitt M;
    Int J Oncol; 2003 Dec; 23(6):1715-26. PubMed ID: 14612946
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Proteomics methods and applications for the practicing clinician.
    Reisdorph NA; Reisdorph R; Bowler R; Broccardo C
    Ann Allergy Asthma Immunol; 2009 Jun; 102(6):523-9. PubMed ID: 19558013
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Biomarker discovery in lung cancer--promises and challenges of clinical proteomics.
    Bharti A; Ma PC; Salgia R
    Mass Spectrom Rev; 2007; 26(3):451-66. PubMed ID: 17407130
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Research issues and strategies for genomic and proteomic biomarker discovery and validation: a statistical perspective.
    Feng Z; Prentice R; Srivastava S
    Pharmacogenomics; 2004 Sep; 5(6):709-19. PubMed ID: 15335291
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Optimizing the Clinical Utility of Biomarkers in Oncology: The NCCN Biomarkers Compendium.
    Birkeland ML; McClure JS
    Arch Pathol Lab Med; 2015 May; 139(5):608-11. PubMed ID: 25333835
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Use of palliative radiotherapy trials for clinical biomarker development.
    Wan J; Milosevic M; Brade AM
    Cancer Metastasis Rev; 2008 Sep; 27(3):435-43. PubMed ID: 18392923
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Proteomics in translational cancer research: biomarker discovery for clinical applications.
    Cho WC
    Expert Rev Proteomics; 2014 Apr; 11(2):131-3. PubMed ID: 24646121
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Basic principles for the development of biomarkers in oncology].
    Seijas R; Herranz J; Malats N
    Arch Esp Urol; 2013 Jun; 66(5):423-31. PubMed ID: 23793760
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Standards in molecular diagnostics for the discovery and validation of clinically useful cancer biomarkers.
    Vydelingum NA; Sorbara L; Wagner P; Srivastava S
    Expert Rev Mol Diagn; 2013 Jun; 13(5):421-3. PubMed ID: 23782249
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Network views for personalized medicine.
    Vlahou A
    Proteomics Clin Appl; 2013 Jun; 7(5-6):384-7. PubMed ID: 23532915
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cancer Biomarkers Discovery and Validation: State of the Art, Problems and Future Perspectives.
    Mordente A; Meucci E; Martorana GE; Silvestrini A
    Adv Exp Med Biol; 2015; 867():9-26. PubMed ID: 26530357
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Urinary protein biomarkers of cancer.
    McNeil BK; Getzenberg RH
    Expert Opin Med Diagn; 2009 May; 3(3):263-73. PubMed ID: 23488462
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.